ID   TTC-466
AC   CVCL_A444
SY   TTC466; TCC466
DR   cancercelllines; CVCL_A444
DR   Cell_Model_Passport; SIDM01911
DR   Cosmic; 759889
DR   Cosmic; 1081765
DR   Cosmic; 2294590
DR   DepMap; ACH-001206
DR   GEO; GSM510014
DR   GEO; GSM1899424
DR   Progenetix; CVCL_A444
DR   Wikidata; Q54973236
RX   PubMed=8162068;
RX   PubMed=16631476;
RX   PubMed=21822310;
RX   PubMed=26428435;
RX   PubMed=26979953;
RX   PubMed=28196595;
RX   PubMed=29464090;
RX   PubMed=30879952;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG; Note=In frame (PubMed=8162068; PubMed=16631476).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (DepMap=ACH-001206).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: TTC-446; PubMed=16631476.
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
ST   Source(s): PubMed=30879952
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 10,12
ST   D16S539: 11,12
ST   D3S1358: 17,18
ST   D5S818: 10
ST   D7S820: 8,10
ST   FGA: 24,25
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M152 ! CHLA-25
SX   Female
AG   4-5Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 24
//
RX   PubMed=8162068; DOI=10.1038/ng0294-146;
RA   Sorensen P.H.B., Lessnick S.L., Lopez-Terrada D.H., Liu X.F.,
RA   Triche T.J., Denny C.T.;
RT   "A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene
RT   to another ETS-family transcription factor, ERG.";
RL   Nat. Genet. 6:146-151(1994).
//
RX   PubMed=16631476; DOI=10.1016/j.cancergencyto.2005.11.006;
RA   Szuhai K., IJszenga M., Tanke H.J., Rosenberg C., Hogendoorn P.C.W.;
RT   "Molecular cytogenetic characterization of four previously established
RT   and two newly established Ewing sarcoma cell lines.";
RL   Cancer Genet. Cytogenet. 166:173-179(2006).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=26979953; DOI=10.1073/pnas.1521251113;
RA   Town J., Pais H., Harrison S., Stead L.F., Bataille C., Bunjobpol W.,
RA   Zhang J., Rabbitts T.H.;
RT   "Exploring the surfaceome of Ewing sarcoma identifies a new and unique
RT   therapeutic target.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:3603-3608(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29464090; DOI=10.18632/oncotarget.23815;
RA   Spurny C., Kailayangiri S., Altvater B., Jamitzky S., Hartmann W.,
RA   Wardelmann E., Ranft A., Dirksen U., Amler S., Hardes J., Fluegge M.,
RA   Meltzer J., Farwick N., Greune L., Rossig C.;
RT   "T cell infiltration into Ewing sarcomas is associated with local
RT   expression of immune-inhibitory HLA-G.";
RL   Oncotarget 9:6536-6549(2018).
//
RX   PubMed=30879952; DOI=10.1016/j.ymthe.2019.02.014;
RA   Kailayangiri S., Altvater B., Lesch S., Balbach S.T., Gottlich C.,
RA   Kuhnemundt J., Mikesch J.-H., Schelhaas S., Jamitzky S., Meltzer J.,
RA   Farwick N., Greune L., Fluegge M., Kerl K., Lode H.N., Siebert N.,
RA   Muller I., Walles H., Hartmann W., Rossig C.;
RT   "EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for
RT   targeting with gene-modified T cells.";
RL   Mol. Ther. 27:933-946(2019).
//